A practical reference on c-Met receptor: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-08-23. Anything still debated is marked as such rather than presented as settled.
Most published work on dihexa consists of preclinical studies using cell cultures or rodents. Reports have described effects on synaptic connectivity and performance on cognitive tasks in some animal models. These findings are generally presented as preliminary and require independent replication. Study designs, doses, and outcome measures vary across experiments, which complicates direct comparison. No large controlled human trials have established efficacy or safety for any medical use. At present, the evidence base is limited.
Regulatory agencies have not approved dihexa as a prescription drug or supplement. In many countries it falls into a gray area when sold for laboratory research. Buyers may encounter products marketed for research use only, which are not intended for human consumption. Purity and identity can vary between suppliers and batches. Certificates of analysis and independent testing are often recommended for research materials. Documentation helps verify what a vial contains.
Discussion of dihexa in online communities sometimes outpaces the scientific record. Anecdotal reports are difficult to verify and may not distinguish effects from placebo or expectation. The absence of approved human data means long-term risks remain unknown. Researchers continue to investigate related compounds and pathways. Open questions include whether animal findings translate to humans and which biological targets matter most. No consensus exists on these points. Current reviews emphasize the need for rigorous clinical research.
Dihexa is a synthetic peptide whose structure is modeled on angiotensin IV. Its chemical name often appears as N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, though vendor and publication naming can differ. The molecule combines a short amino acid sequence with a hexanoic acid group and an amide terminus. It is classed as a small research peptide rather than a conventional drug. Databases may list it under several synonyms, so matching names are important when comparing sources.
The angiotensin IV connection places dihexa in a family of short peptides studied for effects on central nervous system signaling. Angiotensin IV itself is a metabolite of angiotensin II, and analogs have been explored in cardiovascular and neurological research. Dihexa differs from the natural peptide through structural modifications intended to alter stability and receptor interactions. Published descriptions sometimes call it a hepatocyte growth factor mimetic, although that label reflects proposed activity rather than a confirmed clinical mechanism.
| Property | Value | Notes |
|---|---|---|
| Development status | Preclinical research | No approved therapeutic indication has been established. |
| Human data | Limited or absent | Published controlled trials in people are not available. |
| Regulatory classification | Varies by country | Often treated as a research chemical rather than a medicine. |
| Common supply form | Lyophilized powder | Sold for laboratory use, not for human consumption. |
| Quality checks | Certificate of analysis; HPLC; mass spectrometry | Used to verify identity and purity in research settings. |
Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
== Research == Deudimethyltryptamine is under development by Helus Pharma (formerly Cybin). It is under development for the treatment of generalized anxiety disorder, anxiety disorders, and depressive disorders. As of July 2026, deudimethyltryptamine is in phase 2 clinical trials for generalized anxiety disorder and phase 1 trials for anxiety disorders and depressive disorders. It was also under development for the treatment of substance-related disorders and other psychiatric disorders, but development for these indications was discontinued.
Congress reconvenes and formally certifies Joe Biden as the next president of the United States on the morning of January 7. President Trump formally concedes to an orderly transition of power to Joe Biden. During the Electoral College vote count, Senator Ted Cruz and Representative Paul Gosar object to Arizona's election results, the first time a vote is forced to accept or reject the objection since 2004. Representative Scott Perry and Senator Josh Hawley subsequently object to Pennsylvania's election results. January 7 Tesla and SpaceX CEO Elon Musk becomes the world's richest person, with a net worth exceeding $185 billion, surpassing Amazon CEO Jeff Bezos. Facebook indefinitely bans President Donald Trump from all of its platforms, citing his role in the January 6 Capitol riot. Twitter permanently suspends Trump's personal account the next day, January 8. Betsy DeVos resigns as Education Secretary in protest of President Trump's role in the January 6 Capitol riot. January 8 Amid an industry crackdown on extremist content following the January 6 Capitol riot, Google removes the mobile app of social networking service Parler from Google Play. Apple suspends the app from its App Store the next day, January 9. Parler goes offline a day later, January 10, when Amazon ceases to provide its cloud computing services. After 36 years, Alex Trebek's final episode of Jeopardy! airs. Ken Jennings becomes the temporary host on January 11 as the search for a new permanent host continues.
A large number of progestins, or synthetic progestogens, have been derived from progesterone. They can be categorized into several structural groups, including derivatives of retroprogesterone, 17α-hydroxyprogesterone, 17α-methylprogesterone, and 19-norprogesterone, with a respective example from each group including dydrogesterone, medroxyprogesterone acetate, medrogestone, and promegestone. The progesterone ethers quingestrone (progesterone 3-cyclopentyl enol ether) and progesterone 3-acetyl enol ether are among the only examples that do not belong to any of these groups. Another major group of progestins, the 19-nortestosterone derivatives, exemplified by norethisterone (norethindrone) and levonorgestrel, are not derived from progesterone but rather from testosterone. A variety of synthetic inhibitory neurosteroids have been derived from progesterone and its neurosteroid metabolites, allopregnanolone and pregnanolone. Examples include alfadolone, alfaxolone, ganaxolone, hydroxydione, minaxolone, and renanolone. In addition, C3 and C20 conjugates of progesterone, such as progesterone carboxymethyloxime (progesterone 3-(O-carboxymethyl)oxime; P4-3-CMO), P1-185 (progesterone 3-O-(L-valine)-E-oxime), EIDD-1723 (progesterone 20E-[O-[(phosphonooxy)methyl]oxime] sodium salt), EIDD-036 (progesterone 20-oxime; P4-20-O), and VOLT-02 (chemical structure unreleased), have been developed as water-soluble prodrugs of progesterone and its neurosteroid metabolites.
Sources: en.wikipedia.org
==== MeSH E05.196.181 – chromatography ==== MeSH E05.196.181.349 – chromatography, gas MeSH E05.196.181.349.390 – flame ionization MeSH E05.196.181.349.500 – mass fragmentography MeSH E05.196.181.400 – chromatography, liquid MeSH E05.196.181.400.170 – chromatography, affinity MeSH E05.196.181.400.250 – chromatography, gel MeSH E05.196.181.400.250.200 – chromatography, agarose MeSH E05.196.181.400.300 – chromatography, high pressure liquid MeSH E05.196.181.400.383 – chromatography, ion exchange MeSH E05.196.181.400.383.349 – chromatography, deae-cellulose MeSH E05.196.181.400.454 – chromatography, paper MeSH E05.196.181.400.454.655 – nucleotide mapping MeSH E05.196.181.400.454.655.100 – blotting, northern MeSH E05.196.181.400.454.655.150 – blotting, southern MeSH E05.196.181.400.454.720 – peptide mapping MeSH E05.196.181.400.537 – chromatography, thin layer MeSH E05.196.181.400.555 – countercurrent distribution MeSH E05.196.181.500 – chromatography, micellar electrokinetic capillary MeSH E05.196.181.750 – chromatography, supercritical fluid
== Broadband == One of the first DIA approaches was a nozzle-skimmer dissociation method called shotgun collision-induced dissociation (CID). Fragmentation can be in the ion source of the mass spectrometer by increasing the nozzle-skimmer voltage in electrospray ionization. MSE is a broadband DIA technique that uses alternating low-energy CID and high-energy CID. The low-energy CID is used to acquire precursor ion mass spectra whereas the high-energy CID is used to obtain product ion information by tandem mass spectrometry.
In the 1970s, the KGB, led by Yuri Andropov, continued to persecute distinguished Soviet dissidents, such as Aleksandr Solzhenitsyn and Andrei Sakharov, who were criticising the Soviet leadership in harsh terms. Indirect conflict between the superpowers continued through this period of détente in the Third World, particularly during political crises in the Middle East, Chile, Ethiopia, and Angola. In 1973, Nixon announced his administration was committed to seeking most favored nation trade status with the USSR, which was challenged by Congress in the Jackson-Vanik Amendment. The United States had long linked trade with the Soviet Union to its foreign policy toward the Soviet Union and, especially since the early 1980s, to Soviet human rights policies. The Jackson-Vanik Amendment, which was attached to the 1974 Trade Act, linked the granting of most-favored-nation to the USSR to the right of persecuted Soviet Jews to emigrate. Because the Soviet Union refused the right of emigration to Jewish refuseniks, the ability of the President to apply most-favored nation trade status to the Soviet Union was restricted. Although President Jimmy Carter tried to place another limit on the arms race with a SALT II agreement in 1979, his efforts were undermined by the other events that year, including the Iranian Revolution and the Nicaraguan Revolution, which both ousted pro-US governments, and his retaliation against the Soviet coup in Afghanistan in December.
=== January === January 13, 2009: South Korea, Taiwan, Japan, United States Global shipping experiences a drop in trade, as exports from South Korea dropping an annualised 30%, with Taiwan and Japan experiencing a 42% and 27% drop respectively. Outgoing traffic in the United States dropped 18% from Long Beach and Los Angeles.
Sources: en.wikipedia.org
Dividing a compound mixture into equal portions Coupling one different building block (BB) to each portion Pooling and thoroughly mixing the portions The original method is based on the solid-phase synthesis of Merrifield The procedure is illustrated in the figure by the flowing diagram showing of a two-cycle synthesis using the same three BBs in both cycles. Choosing the solid phase method in the S&P synthesis is reasonable since otherwise removal of the by-products from the mixture of compounds would be very difficult.
=== Warfarin === Excessive use of alcohol is known to affect the metabolism of warfarin and can elevate the INR, and thus increase the risk of bleeding. The U.S. Food and Drug Administration (FDA) product insert on warfarin states that alcohol should be avoided. The Cleveland Clinic suggests that when taking warfarin one should not drink more than "one beer, 6 oz of wine, or one shot of alcohol per day".
Luspatercept, sold under the brand name Reblozyl, is a medication used for the treatment of anemia in beta thalassemia and myelodysplastic syndromes. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Sources: en.wikipedia.org
Published human trials are lacking. Most evidence comes from laboratory and animal studies. Therefore, human benefits and risks are not established.
Rules differ by country and by how the product is labeled. Research chemicals are often sold for laboratory use only. Buyers should check local regulations before ordering.
Some animal studies have examined cognitive outcomes, which has led to online interest. These results do not prove cognitive enhancement in people. The term nootropic is not a regulatory category.
Dihexa is a synthetic peptide analog related to angiotensin IV. It is studied in preclinical research for effects on neural signaling and synapse formation. It is not an approved medicine.